Alice Tsang Shaw, MD, PhD, is a thoracic oncologist at the Massachusetts General Hospital Cancer Center.
BiographyAlice T. Shaw, MD, PhD, is an attending physician in the Center for Thoracic Cancers at Massachusetts General Hospital, an assistant professor of medicine at Harvard Medical School, and a clinical investigator at MIT's Koch Institute for Integrative Cancer Research. In addition to caring for patients with lung cancer, Dr. Shaw also performs clinical and translational research.
Dr. Shaw's major research interests include studying anaplastic lymphoma kinase (ALK) translocations in non-small cell lung carcinoma (NSCLS); developing targeted strategies to treat NSCLCs harboring activating KRAS mutations; discovering new targets in NSCLC using both genetic and phosphoproteomic strategies; and developing novel nanoparticle-based siRNA delivery systems to target genetically defined subsets of lung cancer. Dr Shaw has been awarded a number of research grants, including grants from the Damon Runyon Cancer Research Foundation, the Burroughs Welcome Fund, the V Foundation for Cancer Research, and the NIH/NCI.
Alice Shaw, MD, thoracic oncologist at the Mass General Cancer Center, says patients with lung cancer can benefit from genetic testing, particularly if they are young non-smokers. Learn more about personalized treatment for lung cancer and new "smart drugs" that target a tumor's specific genetic mutation to slow the cancer's growth, and in some cases, reduce it significantly.
MGH Cancer Center investigators have defined the role of a recently identified gene abnormality – rearrangements in the ROS1 gene – in non-small-cell lung cancer, the leading cause of cancer death in the U.S. They also show that these tumors can be treated with crizotinib and describe the remarkable response of one patient to such treatment.
The results of a new phase III trial show that crizotinib, a targeted therapy, is a more effective treatment than standard chemotherapy for patients with advanced, ALK-positive lung cancer.
Research teams led by Massachusetts General Hospital (MGH) Cancer Center investigators are publishing two important studies regarding use of the targeted cancer drug crizotinib for treatment of advanced lung cancer driven by specific genetic mutations.